FeesSafety
Pluang+

AVITA Medical to host investor webinar on Nov 11 covering Q3 2026 results and business update

Market News
08 Nov 2026, 22:30 WIB
GlobeNewsWire
View Source
Neutral
AVITA Medical to host investor webinar on Nov 11 covering Q3 2026 results and business update

AVITA Medical announced an investor webinar on November 11, 2026, where CEO Cary Vance and CFO David O’Toole will discuss the company's third-quarter 2026 financial and business results. The session will include a Q&A segment for participants who can submit questions in advance. AVITA Medical specializes in acute wound care technologies, including the FDA-approved RECELL system for burn and trauma wounds. The webinar aims to provide shareholders and prospective investors with insights into recent performance and future outlook. A replay will be available on the company's website after the event.

AVITA Medical's upcoming investor webinar briefing is noted alongside Pluang's Health sector market snapshot as of Nov 09, 2026 00:51 WIB: Among 150 priced Health-sector US stocks, 88 advanced and 62 declined. Notable gainers include ERAS at USD 14.41 (+8.59%), RVMD at USD 192.28 (+8.24%), and HIMS at USD 26.00 (+8.06%), with typical hold times ranging from 4 to 24 days on Pluang.

More News

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.

NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...

Market News
Neutral
41 minutes ago
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
5 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
5 hours ago
Reinvesting dividends turned $1,000 in Procter & Gamble into $4,656 over 20 years.

Reinvesting dividends turned $1,000 in Procter & Gamble into $4,656 over 20 years.

Investing $1,000 in Procter & Gamble (P&G) in 2006 and reinvesting all dividends grew the investment to $4,656 by 2026. P&G's steady demand for everyday products supports 70 consecutive years of dividend increases, with dividends rising from $0.31 to...

Market News
Bullish
5 hours ago
3 stocks with recurring revenue face challenges but offer long-term growth potential.

3 stocks with recurring revenue face challenges but offer long-term growth potential.

Three companies—Otis Worldwide, Rollins, and Republic Services—offer recurring revenue through essential services like elevator maintenance, pest control, and waste management. Despite their steady cash flows and customer loyalty, Otis and Rollins fa...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App